Early diagnosis of chronic kidney disease in patients with diabetes in France : multidisciplinary expert opinion, prevention value and practical recommendations
Diabetes is the leading cause of end-stage kidney disease (ESKD), accounting for approximately 50% of patients starting dialysis. However, the management of these patients at the stage of chronic kidney disease (CKD) remains poor, with fragmented care pathways among healthcare professionals (HCPs). Diagnosis of CKD and most of its complications is based on laboratory evidence. This article provides an overview of critical laboratory evidence of CKD and their limitations, such as estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), Kidney Failure Risk Equation (KFRE), and serum potassium. eGFR is estimated using the CKD-EPI 2009 formula, more relevant in Europe, from the calibrated dosage of plasma creatinine. The estimation formula and the diagnostic thresholds have been the subject of recent controversies. Recent guidelines emphasized the combined equation using both creatinine and cystatin for improved estimation of GFR. UACR on a spot urine sample is a simple method that replaces the collection of 24-hour urine. Albuminuria is the preferred test because of increased sensitivity but proteinuria may be appropriate in some settings as an alternative or in addition to albuminuria testing. KFRE is a new tool to estimate the risk of progression to ESKD. This score is now well validated and may improve the nephrology referral strategy. Plasma or serum potassium is an important parameter to monitor in patients with CKD, especially those on renin-angiotensin-aldosterone system (RAAS) inhibitors or diuretics. Pre-analytical conditions are essential to exclude factitious hyperkalemia. The current concept is to correct hyperkalemia using pharmacological approaches, resins or diuretics to be able to maintain RAAS blockers at the recommended dose and discontinue them at last resort. This paper also suggests expert recommendations to optimize the healthcare pathway and the roles and interactions of the HCPs involved in managing CKD in patients with diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
Postgraduate medicine - 135(2023), 7 vom: 21. Sept., Seite 633-645 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hannedouche, Thierry [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 24.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/00325481.2023.2256208 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362300917 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362300917 | ||
| 003 | DE-627 | ||
| 005 | 20231226090941.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/00325481.2023.2256208 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362300917 | ||
| 035 | |a (NLM)37733403 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hannedouche, Thierry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early diagnosis of chronic kidney disease in patients with diabetes in France |b multidisciplinary expert opinion, prevention value and practical recommendations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Diabetes is the leading cause of end-stage kidney disease (ESKD), accounting for approximately 50% of patients starting dialysis. However, the management of these patients at the stage of chronic kidney disease (CKD) remains poor, with fragmented care pathways among healthcare professionals (HCPs). Diagnosis of CKD and most of its complications is based on laboratory evidence. This article provides an overview of critical laboratory evidence of CKD and their limitations, such as estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), Kidney Failure Risk Equation (KFRE), and serum potassium. eGFR is estimated using the CKD-EPI 2009 formula, more relevant in Europe, from the calibrated dosage of plasma creatinine. The estimation formula and the diagnostic thresholds have been the subject of recent controversies. Recent guidelines emphasized the combined equation using both creatinine and cystatin for improved estimation of GFR. UACR on a spot urine sample is a simple method that replaces the collection of 24-hour urine. Albuminuria is the preferred test because of increased sensitivity but proteinuria may be appropriate in some settings as an alternative or in addition to albuminuria testing. KFRE is a new tool to estimate the risk of progression to ESKD. This score is now well validated and may improve the nephrology referral strategy. Plasma or serum potassium is an important parameter to monitor in patients with CKD, especially those on renin-angiotensin-aldosterone system (RAAS) inhibitors or diuretics. Pre-analytical conditions are essential to exclude factitious hyperkalemia. The current concept is to correct hyperkalemia using pharmacological approaches, resins or diuretics to be able to maintain RAAS blockers at the recommended dose and discontinue them at last resort. This paper also suggests expert recommendations to optimize the healthcare pathway and the roles and interactions of the HCPs involved in managing CKD in patients with diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Healthcare pathway | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a early diagnosis | |
| 650 | 4 | |a estimated glomerular filtration rate | |
| 650 | 4 | |a hyperkalemia | |
| 650 | 4 | |a hypokalemia | |
| 650 | 4 | |a kidney failure risk equation (KFRE) | |
| 650 | 4 | |a urine albumin-to-creatinine ratio (UACR) | |
| 700 | 1 | |a Rossignol, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Darmon, Patrice |e verfasserin |4 aut | |
| 700 | 1 | |a Halimi, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Vuattoux, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Hagege, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Videloup, Ludivine |e verfasserin |4 aut | |
| 700 | 1 | |a Guinard, Francis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Postgraduate medicine |d 1947 |g 135(2023), 7 vom: 21. Sept., Seite 633-645 |w (DE-627)NLM000021792 |x 1941-9260 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2023 |g number:7 |g day:21 |g month:09 |g pages:633-645 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/00325481.2023.2256208 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2023 |e 7 |b 21 |c 09 |h 633-645 | ||